Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Insider Sells $319,598.34 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) insider Joanne Quan sold 6,969 shares of the business’s stock in a transaction on Friday, January 17th. The shares were sold at an average price of $45.86, for a total transaction of $319,598.34. Following the completion of the transaction, the insider now directly owns 5,649 shares in the company, valued at $259,063.14. This represents a 55.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Mirum Pharmaceuticals Trading Up 4.1 %

Shares of MIRM stock opened at $48.65 on Friday. The stock has a market cap of $2.34 billion, a P/E ratio of -24.08 and a beta of 0.98. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $23.14 and a fifty-two week high of $49.27. The business has a fifty day simple moving average of $43.65 and a 200-day simple moving average of $41.40.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The firm had revenue of $90.38 million during the quarter, compared to the consensus estimate of $81.99 million. During the same period last year, the firm posted ($0.57) EPS. The firm’s revenue for the quarter was up 89.4% on a year-over-year basis. On average, analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Robert W. Baird lifted their target price on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Citigroup lifted their price objective on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. HC Wainwright reissued a “buy” rating and set a $66.00 target price on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Finally, Leerink Partners lifted their price target on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $57.10.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Mirum Pharmaceuticals by 22.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock worth $67,000 after acquiring an additional 318 shares during the last quarter. Amalgamated Bank raised its stake in Mirum Pharmaceuticals by 60.8% in the 2nd quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock valued at $46,000 after purchasing an additional 513 shares during the last quarter. R Squared Ltd purchased a new position in Mirum Pharmaceuticals in the 4th quarter valued at about $69,000. Secure Asset Management LLC boosted its stake in shares of Mirum Pharmaceuticals by 9.3% during the 4th quarter. Secure Asset Management LLC now owns 39,920 shares of the company’s stock worth $1,651,000 after purchasing an additional 3,406 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Mirum Pharmaceuticals by 5.7% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,461 shares of the company’s stock worth $2,475,000 after buying an additional 3,442 shares in the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.